TECVAYLI® + TALVEY® reduced the risk of disease progression or death by 89% and the risk of death by 62% in earlier-line relapsed/refractory multiple myeloma
PR Newswire•23/07/2026•08:30 ET
0
Whiz Insights
Get started
Create a free account to read the full story.